Ibuprofen modulates NF-κB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells

Respiration

Volumn 79, Issue 3, 2010, Pages 234-242

  Dauletbaev, Nurlan ^a   Lam, Joyce ^a   Eklove, Daniel ^a   Iskandar, Michele ^a   Lands, Larry C ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

Corticosteroids; Cystic fibrosis; Dexamethasone; Epithelial cells; Ibuprofen; IL 1 ; IL 8; NF B; NSAIDS; TNF ; Transcription factors

Indexed keywords

DEXAMETHASONE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CYSTIC FIBROSIS; EPITHELIAL CELLS; HUMANS; IBUPROFEN; INTERLEUKIN-1BETA; INTERLEUKIN-8; NF-KAPPA B; RESPIRATORY MUCOSA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76749165217     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000255342     Document Type: Article

References (52)

1. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR: Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2: 686-688.
2. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV: A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995; 126: 515-523.
3. Greally P, Hussain MJ, Vergani D, Price JF: Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Arch Dis Child 1994; 71: 35-39.
4. Konstan MW, Byard PJ, Hoppel CL, Davis PB: Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
5. Lands LC, Milner R, Cantin AM, Manson D, Corey M: High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151: 249-254.
6. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, Farrell PM: Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342: 851-859.
7. Chmiel JF, Konstan MW: Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007; 28: 331-346.
8. Kobayashi Y: The role of chemokines in neutrophil biology. Front Biosci 2008; 13: 2400-2407.
9. Dauletbaev N, Gropp R, Frye M, Loitsch S, Wagner TO, Bargon J: Expression of human beta defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult cystic fibrosis patients, healthy individuals, and individuals with acute cold. Respiration 2002; 69: 46-51.
10. Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB: CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 292:L383-L395.
11. Tirouvanziam R, de Bentzmann S, Hubeau C, Hinnrasky J, Jacquot J, Peault B, Puchelle E: Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000; 23: 121-127.
12. Muselet-Charlier C, Roque T, Boncoeur E, Chadelat K, Clement A, Jacquot J, Tabary O: Enhanced IL-1 induced IL-8 production in cystic fibrosis lung epithelial cells is dependent of both mitogen-activated protein kinases and NF B signaling. Biochem Biophys Res Commun 2007; 357: 402-407.
13. Stecenko AA, King G, Torii K, Breyer RM, Dworski R, Blackwell TS, Christman JW, Brigham KL: Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation 2001; 25: 145-155.
14. Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, Davis PB, Hoppel CL: Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003; 306: 1086-1091.
15. Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001; 15: 2057-2072.
16. Konstan MW, Vargo KM, Davis PB: Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis 1990; 141: 186-192.
17. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD: Constitutive activation of I B kinase and NF B in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389-7394.
18. Scheuren N, Bang H, Munster T, Brune K, Pahl A: Modulation of transcription factor NF B by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol 1998; 123: 645-652.
19. Stuhlmeier KM, Li H, Kao JJ: Ibuprofen: new explanation for an old phenomenon. Biochem Pharmacol 1999; 57: 313-320.
20. Roebuck KA: Regulation of interleukin-8 gene expression. J Interferon Cytokine Res 1999; 19: 429-438.
21. Kunzelmann K, Schwiebert EM, Zeitlin PL, Kuo WL, Stanton BA, Gruenert DC: An immortalized cystic fibrosis tracheal epithelial cell line homozygous for the delta F508 CFTR mutation. Am J Respir Cell Mol Biol 1993; 8: 522-529.
22. Southern KW: Cystic fibrosis and formes frustes of CFTR-related disease. Respiration 2007; 74: 241-251.
23. Gruenert DC: Human airway epithelial cell lines and concomitant journal references. http://www.cpmc.org/professionals/research/ programs/science/ celllinereference. pdf.
24. Cozens AL, Yezzi MJ, Yamaya M, Steiger D, Wagner JA, Garber SS, Chin L, Simon EM, Cutting GR, Gardner P: A transformed human epithelial cell line that retains tight junctions post crisis. In Vitro Cell Dev Biol 1992; 28: 735-744.
25. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K: Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 1994; 269: 13289-13295.
26. Huizenga NA, Koper JW, de Lange P, Pols HA, Stolk RP, Grobbee DE, de Jong FH, Lamberts SW: Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamopituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab 1998; 83: 47-54.
27. Weijtens O, Schoemaker RC, Cohen AF, Romijn FP, Lentjes EG, van Rooij J, van Meurs JC: Dexamethasone concentration in vitreous and serum after oral administration. Am J Ophthalmol 1998; 125: 673-679.
28. Gruenert DC, Basbaum CB, Welsh MJ, Li M, Finkbeiner WE, Nadel JA: Characterization of human tracheal epithelial cells transformed by an origin-defective simian virus 40. Proc Natl Acad Sci USA 1988; 85: 5951-5955.
29. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 C T method. Methods 2001; 25: 402-408.
30. John G, Yildirim AO, Rubin BK, Gruenert DC, Henke MO: Toll-like receptor (TLR)-4 mediated innate immunity is reduced in cystic fibrosis airway cells. Am J Respir Cell Mol Biol, E-pub ahead of print.
31. Dong JQ, Ni L, Scott CS, Retsch-Bogart GZ, Smith PC: Pharmacokinetics of ibuprofen enantiomers in children with cystic fibrosis. J Clin Pharmacol 2000; 40: 861-868.
32. Chivers JE, Gong W, King EM, Seybold J, Mak JC, Donnelly LE, Holden NS, Newton R: Analysis of the dissociated steroid RU24858 does not exclude a role for inducible genes in the anti-inflammatory actions of glucocorticoids. Mol Pharmacol 2006; 70: 2084-2095.
33. LeVan TD, Behr FD, Adkins KK, Miesfeld RL, Bloom JW: Glucocorticoid receptor signaling in a bronchial epithelial cell line. Am J Physiol 1997; 272: 838-843.
34. Nie M, Knox AJ, Pang L: 2 -Adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J Immunol 2005; 175: 478-486.
35. Bartoszewski R, Rab A, Jurkuvenaite A, Mazur M, Wakefield J, Collawn JF, Bebok Z: Activation of the unfolded protein response by F508 CFTR. Am J Respir Cell Mol Biol 2008; 39: 448-457.
36. Vij N, Fang S, Zeitlin PL: Selective inhibition of endoplasmic reticulum-associated degradation rescues F508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 2006; 281: 17369-17378.
37. Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, Nagata K, Harding HP, Ron D: CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004; 18: 3066-3077.
38. Vij N, Amoako MO, Mazur S, Zeitlin PL: CHOP transcription factor mediates IL-8 signaling in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2008; 38: 176-184.
39. Furst SM, Khan KN, Komocsar WJ, Fan L, Mennear J: Screening new drugs for immunotoxic potential. II. Assessment of the effects of selective and nonselective COX-2 inhibitors on complement activation, superoxide anion production and leukocyte chemotaxis and migration through endothelial cells. J Immunotoxicol 2005; 2: 85-96.
40. Li J, Xiang YY, Ye L, Tsui LC, Macdonald JF, Hu J, Lu WY: Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. Eur Respir J 2008; 32: 334-343.
41. Chmiel JF, Berger M, Konstan MW: The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23: 5-27.
42. Jacquot J, Tabary O, Le RP, Clement A: Airway epithelial cell inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol 2008; 40: 1703-1715.
43. Escotte S, Tabary O, Dusser D, Majer-Teboul C, Puchelle E, Jacquot J: Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-beta kinase pathway. Eur Respir J 2003; 21: 574-581.
44. Kube D, Sontich U, Fletcher D, Davis PB: Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001; 280:L493-L502.
45. Fink J, Steer JH, Joyce DA, McWilliam AS, Stewart GA: Pro-inflammatory effects of Burkholderia cepacia on cystic fibrosis respiratory epithelium. FEMS Immunol Med Microbiol 2003; 38: 273-282.
46. Tabary O, Zahm JM, Hinnrasky J, Couetil JP, Cornillet P, Guenounou M, Gaillard D, Puchelle E, Jacquot J: Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol 1998; 153: 921-930.
47. Kammouni W, Figarella C, Marchand S, Merten M: Altered cytokine production by cystic fibrosis tracheal gland serous cells. Infect Immun 1997; 65: 5176-5183.
48. Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, Boucher RC, Cohn JA, Wilson JM: Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 1992; 2: 240-248.
49. 2 and tumor necrosis factor induce differential binding of the redoxresponsive transcription factors AP-1 and NF B to the interleukin-8 promoter in endothelial and epithelial cells. J Biol Chem 1998; 273: 32670-32678.
50. Park SK, Yang WS, Han NJ, Lee SK, Ahn H, Lee IK, Park JY, Lee KU, Lee JD: Dexamethasone regulates AP-1 to repress TNF induced MCP-1 production in human glomerular endothelial cells. Nephrol Dial Transplant 2004; 19: 312-319.
51. Mukaida N, Shiroo M, Matsushima K: Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol 1989; 143: 1366-1371. (Pubitemid 19211374)
52. Chang MM, Juarez M, Hyde DM, Wu R: Mechanism of dexamethasone-mediated interleukin-8 gene suppression in cultured airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2001; 280:L107-L115.